Abstract 536TiP
Background
MET amplification (METamp) is a resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs) occurring via over activation of downstream signaling pathways such as PI3K and MAPK. METamp occurs in ≈10% of patients receiving erlotinib, gefitinib, afatinib, or icotinib, and is the most common resistance mechanism to osimertinib in phase III trials, occurring in ≈19% of patients. Tepotinib, an oral once daily potent and selective MET inhibitor, is associated with improved survival in combination with gefitinib in patients with EGFR-mutant MET-amplified NSCLC with EGFR TKI resistance compared with standard chemotherapy in the INSIGHT study (NCT01982955): investigator-reported progression free survival (PFS) was 21.2 vs 4.2 months (HR 0.13; 90% CI 0.04, 0.43) and overall survival, (OS) was 37.3 vs. 13.1 months (HR 0.08; 90% CI 0.01, 0.51).
Trial design
INSIGHT 2 (NCT03940703) is a global single-arm, open-label, phase II trial of tepotinib in patients with advanced (stage IIIB/IV) NSCLC with resistance to 1st–3rd generation EGFR TKIs driven by METamp. Eligibility criteria include patients aged ≥18 years with advanced EGFR-mutant NSCLC and known T790M status, having acquired resistance to EGFR TKIs, and are METamp positive by plasma ‘liquid’ biopsy, with an ECOG PS of 0 or 1 and normal organ function. Prior immunotherapy is permitted but prior MET pathway-targeted therapy is not. Tepotinib (500 mg orally once daily) in combination with osimertinib (80 mg once daily) will be administered until disease progression, unacceptable toxicity, or withdrawal of consent. An initial safety run-in will comprise 6 patients (endpoint; dose-limiting toxicities); anticipated full enrollment is 90 patients. The primary endpoint is objective response rate (ORR) by independent review committee (RECIST v1.1). Secondary objectives include investigator-assessed ORR, duration of response, disease control, PFS, OS, pharmacokinetics, health-related quality of life, tolerability, and safety (NCI-CTCAE v5.0). Recruitment is ongoing and approximately 80 study sites in 17 countries in Europe, Asia, and North America are expected to participate in this study.
Clinical trial identification
NCT03940703.
Legal entity responsible for the study
Merck Healthcare KGaA.
Funding
Merck Healthcare KGaA.
Disclosure
J.C-H. Yang: Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Roche/Genentech/Chugai; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Merck Serono; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Advisory / Consultancy: Merrimack; Honoraria (self), Advisory / Consultancy: Yuhan Pharmaceuticals; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Ono Pharmaceutical; Honoraria (self), Advisory / Consultancy: Daiichi Sankyo ; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Takeda Oncology; Honoraria (self), Advisory / Consultancy: Blueprint Medicines; Honoraria (self), Advisory / Consultancy: Hansoh Pharmaceuticals. B. Ellers-Lenz: Full / Part-time employment: Merck Healthcare KGaA. J. Straub: Full / Part-time employment: Merck Healthcare KGaA. A. Johne: Full / Part-time employment: Merck Healthcare KGaA. Y-L. Wu: Honoraria (self), Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Boehringer Ingelheim; Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self): Eli Lilly; Honoraria (self): Pfizer; Honoraria (self): Pierre Fabre; Honoraria (self): Sanofi.
Resources from the same session
4P - Impact of chemotherapy and radiotherapy on tissue expander or implant removal in breast cancer patients
Presenter: Sungmi Jung
Session: Poster display session
Resources:
Abstract
5P - Long-term prognostic effect of hormone receptor subtype on breast cancer
Presenter: Ki-tae Hwang
Session: Poster display session
Resources:
Abstract
6P - Effect of apparent diffusion coefficient in predicting pathologic responses in patients with breast cancer treated with neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel
Presenter: Yutaka Mizuno
Session: Poster display session
Resources:
Abstract
7P - Current diagnostic strategy for mammographic microcalcification without specific ultrasound abnormality
Presenter: Naoki Sato
Session: Poster display session
Resources:
Abstract
8P - Comparison of standard uptake value of 18F-FDG-PET-CT with tumour-infiltrating lymphocytes in breast cancer ≥1cm
Presenter: Soeun Park
Session: Poster display session
Resources:
Abstract
10P - Prognosis and effect of adjuvant treatment in small, node(-), HER2(+) breast cancer
Presenter: Seungtaek Lim
Session: Poster display session
Resources:
Abstract
11P - The prognosis of rare histopathologic subtype of breast cancer
Presenter: Soo Youn Bae
Session: Poster display session
Resources:
Abstract
12P - Daily collection of physical activity via smartphone application and smart band for development of distress screening tools in breast cancer survivors: A feasibility study
Presenter: Yungil Shin
Session: Poster display session
Resources:
Abstract
13P - Breast cancer distribution in East Azerbaijan, Iran: Results of population-based cancer registry
Presenter: Shima Pashaei
Session: Poster display session
Resources:
Abstract
14P - Validation of the optimum timing of assessment of tumour infiltrating lymphocytes during preoperative chemotherapy for breast cancer
Presenter: Shinichiro Kashiwagi
Session: Poster display session
Resources:
Abstract